CBS 2019
CBSMD教育中心
HOME
CBS 2019
At CBS
General Information
Association and Affiliations
Organized by
Nanjing Heart Center
Asian Bifurcation Club (ABC)
Nanjing First Hospital, Nanjing Medical University
Co-organized by
Chinese Society of Cardiology (CSC)
Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
American Society for Cardiovascular Angiography and Interventions (SCAI)
Asian Heart Society (AHS)
Contact Us
Registration Administration of Domestic Representatives
Hongjuan Peng :
+86-13913895477
Haimei Xu +86-13914736846
cbsnj@cbsmd.cn
Registration Administration of Overseas Representatives
Ling Lin : +86 (25) 52271398
+86-13951884596
cbs@cbsmd.cn
Management of Challenging Cases
Yingying Zhao :+86-13815408517
sub@cbsmd.cn
Address
CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China
210006
FACULTY
FACULTY
General Chairman
Congress Chairman
Education Center
Education Center
• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)
• CBS Education Resource
• CBSMD Scientific Library
SCIENTIFIC LIBRARY
SCIENTIFIC LIBRARY
Research Paper
> Acute Coronary Syndrom
> ASCVD Prevention
> Bifurcation Stenting
> Cardio-Oncology
> Congestive Heart Failure
> DAPT Duration
> Drug Coated Balloon
> Fractional Flow Reserve
> IVUS Guidance
> Optical Coherence Tomography
> Pulmonary Hypertension
> Rotational Atherectomy
> Shear Stress
> Stenting Left Main
> Transcatheter Aortic Valve Replacement
> Percutaneous LAA Occlusion
> Mitral/Tricuspid Valvular Disease
> Other Relevant Articles
Recommended Paper
Management of Acute Myocardial Infarction During the COVID-19 Pandemic
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic
ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)
Guideline | By V. Aboyans, J-B Ricco, M-L E. L. Bartelink et al.
Subclinical Atherosclerosis Burden by 3D Ultrasound in Mid-Life: The PESA Study
Clinical Trial | By López-Melgar B, Fernández-Friera L, Fuster V
Background - Detection of subclinical atherosclerosis improves risk prediction beyond cardiovascular risk factors (CVRFs) and risk scores, but quantification of plaque burden may improve it further. Novel 3-dimensional vascular ultrasound (3DVUS) provides accurate volumetric quantification of plaque burden. Methods - The authors included 3,860 (92.2%) PESA (Progression of Early Subclinical Atherosclerosis) study participants ...
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
Clinical Trial | By Cannon CP, Bhatt DL, Oldgren J et al.
Background - Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of bleeding. Methods - In this multicenter trial, we randomly assigned 2725 patients with atrial fibrillation who had undergone PCI to triple therapy with warfarin plus a P2...
Oxygen Therapy in Suspected Acute Myocardial Infarction
Original Research | By Hofmann R, James SK, Jernberg T et al.
Background - The clinical effect of routine oxygen therapy in patients with suspected acute myocardial infarction who do not have hypoxemia at baseline is uncertain. Methods - In this registry-based randomized clinical trial, we used nationwide Swedish registries for patient enrollment and data collection. Patients with suspected myocardial infarction and an oxygen saturation of 90% or higher were randomly assign...
Clinical Trial | By Cuisset T, Deharo P, Quilici J et al.
AIMS - Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS). However, both drugs are associated with an increase in bleeding complications. The objective of the present study was to evaluate the benefit of switching dual antiplatelet therapy (DAPT) from aspirin plus a newer P2Y12 blocker to aspirin plus clopidogrel 1 month, were assigned to switch...
Clinical Trial | By Song Y, Gao Z, Tang X et al.
Objective - This study aimed to assess the prognostic ability of synergy between percutaneous coronary intervention with Taxus and cardiac surgery score II (SS-II) in a large cohort of patients with complex coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) in clinical practice. Background - Few studies have explored the usefulness of SS-II in nonrandomized clinical patients with...
Clinical Trial | By Sibbing D, Aradi D, Jacobshagen C et al.
Background - Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous coronary intervention (PCI). However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment. Hence, a stage-adapted treatment with potent platelet inhibition...
Clinical Trial | By Wang X, Matsumura M, Mintz GS et al.
OBJECTIVES - The aim of this study was to evaluate optical coherence tomography (OCT) and intravascular ultrasound (IVUS) versus coronary angiography in the assessment of target lesion calcification and its effect on stent expansion. BACKGROUD - IVUS is more sensitive than angiography in the detection of coronary artery calcium, but the relationship among IVUS, OCT, and angiography h...
Review Article | By Khan MR, Kayani WT, Alam M et al.
Patients with unprotected left main coronary artery (ULMCA) disease are increasingly being treated with percutaneous coronary intervention (PCI) using drug-eluting stents (DES), but long-term outcomes comparing PCI with coronary artery bypass grafting (CABG) remain limited. We performed aggregate data meta-analyses of clinical outcomes (all-cause death, nonfatal myocardial infarction, stroke, repeat revascularization, cardiac death, and majo...
中 文
CBS 2019
CBS 2019 FACULTY
Education Resource
CBSMD Scientific Library
